Grünenthal Agreement for rights to Nexium, Vimovo
30 October 2018 07:00 GMT Agreement with Grünenthal for rights toNexium in Europe and Vimovo worldwide (ex-US) Divestments to support AstraZeneca's focus on three main therapy areas AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo(naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Nexium has lost compound patent protection in the majority of